SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.
SpectraCure AB (publ) reported revenue of 0 SEK for fiscal year 2025, and net income of -56.08 million SEK.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.